drugset / Trial / NCT01968629

24hr Imaging Of HCC After EOVIST

NCT01968629

Phase 0 Withdrawn Massachusetts General Hospital
NaSingle-groupOpen-labelDiagnostic

Summary

In this research study, the investigators are looking to see if MR imaging with Eovist performed 24 hours after the injection of Eovist helps improve the identification and characterization of focal liver tumors.

Timeline

Start
2013-12
Primary completion
2015-07
Completion
2015-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Gadoxetate Disodium Diagnostic / imaging agent 0.1 unknown